A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-30

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare three finished products of PF-06954522 in terms of the uptake into the blood stream.

This study is seeking participants who are:

\- Healthy male or female participants aged 18 years or older.

All participants in this study will receive PF-06954522 once by mouth. The participants may receive different tablets by mouth for PF-06954522.

The study will compare experiences of people receiving three different products of PF-06954522. This will help understand how much PF-06954522 is taken up into the blood for each product given.

Participants will take part into the study for about 77 days. During this time participants will have to stay onsite for 21 days. There will be one follow up (by telephone) study visit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

NCT06670170

Healthy Volunteers

COMPLETED PHASE1

A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults

NCT06190561

Healthy

COMPLETED PHASE1

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

NCT06003777

Healthy Participants

COMPLETED PHASE1

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

NCT03492697

Healthy Subjects

COMPLETED PHASE1

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

NCT03372044

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence 1

Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:

Formulation 1 , Formulation 2, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively.

Group Type EXPERIMENTAL

PF-06954522 IR (Formulation 1)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

PF-06954522 MR (Formulation 2)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

PF-06954522 MR (Formulation 3)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Sequence 2

Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:

Formulation 2, Formulation 3, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively.

Group Type EXPERIMENTAL

PF-06954522 IR (Formulation 1)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

PF-06954522 MR (Formulation 2)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

PF-06954522 MR (Formulation 3)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Sequence 3

Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:

Formulation 3, Formulation 1, and Formulation 2, under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 2 and 3 under fed conditions in Periods 4 and 5, respectively.

Group Type EXPERIMENTAL

PF-06954522 IR (Formulation 1)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

PF-06954522 MR (Formulation 2)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

PF-06954522 MR (Formulation 3)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Sequence 4

Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:

Formulation 3, Formulation 2, and Formulation 1 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively.

Group Type EXPERIMENTAL

PF-06954522 IR (Formulation 1)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

PF-06954522 MR (Formulation 2)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

PF-06954522 MR (Formulation 3)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Sequence 5

Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:

Formulation 1, Formulation 3, and Formulation 2 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively.

Group Type EXPERIMENTAL

PF-06954522 IR (Formulation 1)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

PF-06954522 MR (Formulation 2)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

PF-06954522 MR (Formulation 3)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Sequence 6

Participants will receive a single dose (Dose Level 1 and 2) of PF-06954522 as:

Formulation 2, Formulation 1, and Formulation 3 under fasted conditions in Periods 1, 2, and 3, respectively, followed by Formulations 3 and 2 under fed conditions in Periods 4 and 5, respectively.

Group Type EXPERIMENTAL

PF-06954522 IR (Formulation 1)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

PF-06954522 MR (Formulation 2)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

PF-06954522 MR (Formulation 3)

Intervention Type DRUG

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-06954522 IR (Formulation 1)

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

Intervention Type DRUG

PF-06954522 MR (Formulation 2)

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

Intervention Type DRUG

PF-06954522 MR (Formulation 3)

Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female participants of non-childbearing potential aged 18 years or older who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and electrocardiograms.
* Body mass index of 16-32 kg/m2; and a total body weight \>50 kg (110 lbs).

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2, or participants with suspected MTC per the investigator's judgement.
* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Use of any prohibited prior/concomitant medication(s).
* A positive urine drug test at screening or admission.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes